U.S. Medicare's Second Round of Drug Price Negotiations Delivers 'Historic' Cuts, with Up to 85% Reductions

August 2024, completed in the United StatesFirst Round of Price Negotiations for Medical Insurance Drugs, Eliquis (apixaban), Farxiga (dapagliflozin), Imbruvica (ibrutinib), etc.10 DrugsIncluded in the price reduction list, with price reductions ranging betweenBetween 38% and 79%。

November 25, 2025According to foreign media reports, the US Centers for Medicare & Medicaid Services (CMS) further announcedResults of the Second Round of Medical Insurance Negotiations。

This medical insurance involvesAndTotal15 pharmaceutical products, covering chronic diseases such as cancer, diabetes, and asthma。From the negotiation results, this round of negotiations15Among the drugs11At leastReduced by half, with the maximum reduction reaching85%。

Specifically,MerckOld Brand Hypoglycemic DrugJanumet/Janumet XR (Sitagliptin + Metformin)Became the object of the fiercest "price-cutting" in this round. Monthly treatment costsDropped directly from $526 to $80`, with a reduction of up to 85%.`

Boehringer IngelheimThe DPP-4 inhibitor Tradjenta (linagliptin)A decrease of 84%。GSKThe Respiratory System Blockbuster Breo Ellipta (Fluticasone Furoate + Vilanterol)83% reduction。

In addition,AbbVieConstipation Treatment Drug Linzess (Linaclotide),A 75% reduction。GSKAnother respiratory drugTrelegy Ellipta, Reduction73%。Novo NordiskOzempic (Semaglutide)，A 71% decrease。AmgenPsoriasis Oral MedicationOtezla，A 65% decrease。

This round of medical insurance negotiations is expected to be valid until 2027.Save 36%, which is more than Goldman Sachs' estimate of the net expenditure achieved in Medicare's first round of price negotiations last year for 10 different drugs.Save 22%More impressive.

Just over half a month ago, Trump had just reached an agreement with Novo Nordisk on a platform directly targeting consumers. TrumpRx Above withMonthly350DollarPrice Provided Wegovy, slightly lower than the price reached in this negotiation385USD.

Government administrative measures plusThe Inflation Reduction Act (IRA）The常态化医保谈判below, the dual-pronged approach demonstrates the U.S. government's determination to lower drug prices, of course,The more profound impact is that, as the world's largest pharmaceutical market, the certainty of pharmaceutical companiesThe StrongestSource of profit,U.S. drug pricing has now become unpredictable.

Notably, the next round of Medicare drug price negotiations is expected to include 15 additional prescription drugs and hospital medications, starting in February.